Competitive NMDA receptor antagonist that displays moderate selectivity for NR2A-containing receptors (Ki values are 0.13, 0.47, 1.10 and 3.86 μM for NR2A, NR2B, NR2C and NR2D subunits respectively).
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 251.22. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.98 mL||19.9 mL||39.81 mL|
|5 mM||0.8 mL||3.98 mL||7.96 mL|
|10 mM||0.4 mL||1.99 mL||3.98 mL|
|50 mM||0.08 mL||0.4 mL||0.8 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Benveniste and Mayer (1992) Effect of extracellular pH on the potency of N-methyl-D-aspartic acid receptor competitive antagonists. Mol.Pharmacol. 42 679 PMID: 1435743
Feng et al (2005) The effect of competitive antagonist chain length on NMDA receptor subunit selectivity. Neuropharmacology 48 354 PMID: 15721167
Kinarsky et al (2005) Identification of subunit- and antagonist-specific amino acid residues in the N-methyl-D-aspartate receptor glutamate-binding pocket. J.Pharmacol.Exp.Ther. 313 1066 PMID: 15743930
If you know of a relevant reference for PPPA, please let us know.
View Related Products by Product Action
Keywords: Competitive NR2A antagonists Glutamate NMDA Receptors N-Methyl-D-Aspartate iGluR Ionotropic LY257883 LY 257883 NMDA Receptors
1 Citation for PPPA
Citations are publications that use Tocris products. Selected citations for PPPA include:
Liu et al (2015) The distinct role of NR2B subunit in the enhancement of visual plasticity in adulthood. Mol Brain 8 49 PMID: 26282667
Do you know of a great paper that uses PPPA from Tocris? If so please let us know.
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.